112 related articles for article (PubMed ID: 10565031)
1. Cellular pharmacology of antisense oligodeoxynucleotides.
Schumacher C
Methods Enzymol; 2000; 314():440-54. PubMed ID: 10565031
[No Abstract] [Full Text] [Related]
2. Exposure of human vascular smooth muscle cells to Raf-1 antisense oligodeoxynucleotides: cellular responses and pharmacodynamic implications.
Schumacher C; Cioffi CL; Sharif H; Haston W; Monia BP; Wennogle L
Mol Pharmacol; 1998 Jan; 53(1):97-104. PubMed ID: 9443936
[TBL] [Abstract][Full Text] [Related]
3. Antisense inhibition of sodium-calcium exchanger.
Slodzinski MK; Juhaszova M
Methods Enzymol; 2000; 314():313-23. PubMed ID: 10565022
[No Abstract] [Full Text] [Related]
4. Anti-tumor activity of C-raf antisense--correction.
Monia BP
Nat Med; 1999 Feb; 5(2):127. PubMed ID: 9930845
[No Abstract] [Full Text] [Related]
5. First- and second-generation antisense oligonucleotide inhibitors targeted against human c-raf kinase.
Monia BP
Ciba Found Symp; 1997; 209():107-19; discussion 119-23. PubMed ID: 9383572
[TBL] [Abstract][Full Text] [Related]
6. Comparison of strategies targeting Raf-1 mRNA in ovarian cancer.
Mullen P; McPhillips F; Monia BP; Smyth JF; Langdon SP
Int J Cancer; 2006 Mar; 118(6):1565-71. PubMed ID: 16184551
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of C-raf expression by antisense oligonucleotides extends heart allograft survival in rats.
Stepkowski SM; Qu X; Wang ME; Tian L; Chen W; Wancewicz EV; Johnston JF; Bennett CF; Monia BP
Transplantation; 2000 Aug; 70(4):656-61. PubMed ID: 10972225
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides.
Bennett MR; Anglin S; McEwan JR; Jagoe R; Newby AC; Evan GI
J Clin Invest; 1994 Feb; 93(2):820-8. PubMed ID: 8113414
[TBL] [Abstract][Full Text] [Related]
9. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).
O'Dwyer PJ; Stevenson JP; Gallagher M; Cassella A; Vasilevskaya I; Monia BP; Holmlund J; Dorr FA; Yao KS
Clin Cancer Res; 1999 Dec; 5(12):3977-82. PubMed ID: 10632328
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA
Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
[TBL] [Abstract][Full Text] [Related]
11. Antisense oligodeoxynucleotides downregulated c-sis mRNA expression to inhibit proliferation of vascular smooth muscle cells.
Tang QD; Lin SG; Yu XY
Zhongguo Yao Li Xue Bao; 1999 Jan; 20(1):36-42. PubMed ID: 10437122
[TBL] [Abstract][Full Text] [Related]
12. Use of antisense oligonucleotides in human neuronal and astrocytic cultures.
Sogos V; Curto M; Setzu M; Mussini I; Ennas MG; Gremo F
Methods Enzymol; 2000; 314():247-60. PubMed ID: 10565018
[No Abstract] [Full Text] [Related]
13. Analysis of cancer gene functions through gene inhibition with antisense oligonucleotides.
Robinson-Benion C; Jensen RA; Holt JT
Methods Enzymol; 2000; 314():499-506. PubMed ID: 10565035
[No Abstract] [Full Text] [Related]
14. [The effect of c-myc antisense oligodeoxynucleotides on proliferation of pulmonary arterial smooth muscle cells stimulated by hypoxic endothelial cells conditioned medium].
Tao Q; Zhang Z
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Mar; 21(3):157-9. PubMed ID: 11263352
[TBL] [Abstract][Full Text] [Related]
15. Application of antisense oligodeoxynucleotides for suppression of Na+/Ca2+ exchange.
Schwaller B; Egger M; Lipp P; Niggli E
Methods Enzymol; 2000; 314():454-76. PubMed ID: 10565032
[No Abstract] [Full Text] [Related]
16. Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human disease.
Green DW; Roh H; Pippin J; Drebin JA
J Am Coll Surg; 2000 Jul; 191(1):93-105. PubMed ID: 10898188
[No Abstract] [Full Text] [Related]
17. Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo.
Gokhale PC; McRae D; Monia BP; Bagg A; Rahman A; Dritschilo A; Kasid U
Antisense Nucleic Acid Drug Dev; 1999 Apr; 9(2):191-201. PubMed ID: 10355825
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).
Stevenson JP; Yao KS; Gallagher M; Friedland D; Mitchell EP; Cassella A; Monia B; Kwoh TJ; Yu R; Holmlund J; Dorr FA; O'Dwyer PJ
J Clin Oncol; 1999 Jul; 17(7):2227-36. PubMed ID: 10561280
[TBL] [Abstract][Full Text] [Related]
19. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
[TBL] [Abstract][Full Text] [Related]
20. Gene functional analysis in nervous system.
Hallböök F; Catsicas M; Staple JK; Grenningloh G; Catsicas S
Methods Enzymol; 2000; 314():148-67. PubMed ID: 10565011
[No Abstract] [Full Text] [Related]
[Next] [New Search]
